Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GSK

GSK.LGB00BN7SWP63London SEGBGBP
Stock price
GSK
Loading chart...

Coverage

Latest articles

GSK upgrades 2025 outlook on strong sales and Blenrep approval
29 Oct 2025, 07:03GSK.LLondon SE

Filings

Recent filings

FilingDate
Notice of AGM24 Mar 2025
Transaction in Own Shares21 Mar 2025
Director/PDMR Shareholding21 Mar 2025
Transaction in Own Shares20 Mar 2025
Transaction in Own Shares19 Mar 2025
Transaction in Own Shares18 Mar 2025
Transaction in Own Shares17 Mar 2025
Transaction in Own Shares14 Mar 2025
Director/PDMR Shareholding
Search

GSK raised its full-year 2025 forecast on Wednesday, citing strong sales of its specialty medicines and vaccines and recent drug approvals, including for its cancer treatment Blenrep.

GSK's Blenrep wins FDA approval for multiple myeloma
24 Oct 2025, 06:02GSK.LLondon SE

GSK said Thursday its cancer drug Blenrep won U.S. approval to treat adults with multiple myeloma that has returned or stopped responding to treatment, overcoming an earlier negative recommendation from a regulatory advisory panel.

GSK's new inhaler significantly cuts carbon emissions
22 Oct 2025, 06:06GSK.LLondon SE

GSK announced positive late-stage trial results for a new, low-carbon version of its widely used Ventolin asthma inhaler.

GSK, Alector's dementia drug fails late-stage trial
22 Oct 2025, 06:02GSK.LLondon SE

GSK and partner Alector said Tuesday their experimental drug for a rare form of dementia failed to meet its main goal in a late-stage trial.

First oral carbapenem for complicated UTIs could transform care
21 Oct 2025, 06:02GSK.LLondon SE

GSK and Spero Therapeutics on Tuesday announced positive late-stage trial results for their investigational oral antibiotic, tebipenem HBr, for treating complicated urinary tract infections (cUTIs).

GSK's Shingrix vaccine approved for at-risk adults in China
14 Oct 2025, 06:02GSK.LLondon SE

GSK said on Tuesday that its shingles vaccine, Shingrix, has been approved in China for adults aged 18 and over who are at an increased risk of the disease.

  • Previous
  • 1
  • 2
  • Next
14 Mar 2025
Transaction in Own Shares13 Mar 2025
Transaction in Own Shares12 Mar 2025
Transaction in Own Shares11 Mar 2025
  • Previous
  • 1
  • More pages
  • 20
  • 21
  • 22
  • More pages
  • 43
  • Next
Company
GSK
GSK.LLondon SE
Website: Unavailable
Coverage
9
Filings
508